Clomiphene in Males With Prolactinomas and Persistent Hypogonadism
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
Prolactinomas are usually associated with hypogonadotropic hypogonadism in both sexes.
Clomiphene citrate is a well known selective estrogen receptor modulator that increases
gonadotropin secretion via hypothalamic-pituitary action. We conducted a prospective, open
label clinical trial of CC to evaluate its effects in reverting persistent HH in male
patients with prolactinomas under dopaminergic agonist treatment.